Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Collegium Pharmaceutical reports record 2022 performance and outlines growth strategies

Collegium Pharmaceutical's strong 2022 performance and strategic acquisitions position it for continued success in 2023 with a focus on growth.
The company's commercial strengths in key products like BELBUCA and Xtampza ER drive revenue and showcase growth potential.
Challenges in managing leverage, accelerating franchise growth, and navigating market dynamics are balanced by opportunities for expansion and innovation.
Analysts' inquiries reflect interest in Collegium Pharmaceutical's strategies, market positioning, and response to regulatory changes for future growth.

Collegium Pharmaceutical reports record Q1 revenue amidst patent challenges

Collegium Pharmaceutical's Q1 2023 performance showcased record revenue and strong financial management strategies.
The company faces challenges from patent infringement risks and generic competition, requiring a focus on defending IP and market positioning.
Opportunities in volume growth, business development, and strategic investments in key products position Collegium for long-term success.
Maintaining a balance between defending IP, managing expenses, and driving growth will be crucial for Collegium's future performance.

Collegium Pharmaceutical posts record revenue and growth, eyes strategic acquisitions

Collegium Pharmaceutical reported strong financial performance in Q2 2023, with a focus on achieving a banner year. Despite challenges with Xtampza ER and growth expectations, the company remains committed to improving access, reducing debt, and returning capital to shareholders.

Collegium Pharmaceutical excels in Q3, eyes growth opportunities ahead

Collegium Pharmaceutical reports strong Q3 2023 performance with record revenue and EBITDA growth, driven by successful contract renegotiations and operational efficiency.
Challenges include mitigating declining scripts, navigating patient profiles, and sustaining growth amidst market uncertainties, requiring strategic adjustments and foresight.
Opportunities lie in Medicare Part D market expansion, differentiated asset focus, and strategic valuations, positioning Collegium for future growth and market leadership.

Collegium Pharmaceutical reports record revenue and strategic wins in pain management market

Collegium Pharmaceutical's Q4 2023 earnings call highlighted exceptional financial achievements, robust product performance, and strategic wins in the pain management market. While facing challenges in maintaining guidance and addressing analyst queries, the company remains optimistic about its future outlook and growth potential.

Collegium Pharmaceutical reports strong Q1 earnings amidst leadership transition

Collegium Pharmaceutical's Q1 2024 earnings call highlighted strong financial performance, leadership transition, and growth strategies.
Despite challenges such as CEO resignation and competitive landscape dynamics, the company remains focused on its market position and growth potential.
Opportunities for business development priorities and strategic partnerships offer avenues for future growth and expansion.

Collegium Pharmaceutical reports record Q3 performance and navigates market challenges

Collegium Pharmaceutical's Q3 performance showcased robust financial results and strategic moves to strengthen their market position. While facing challenges in formulary changes and market competition, the company is well-positioned to leverage opportunities in the ADHD market and drive continued growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

STOUGHTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has reached a settlement agreement with Teva Pharmaceutical USA, Inc. (Teva) that resolves patent litigation brought in response to Teva’s Abbreviated New Drug Application (ANDA), seeking approval to market a generic version of Xtampza ER prior to the expiration of Collegium’s applicable patents.

Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation

STOUGHTON, Mass., Sept.  25, 2020  (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Rita Balice-Gordon to its Board of Directors, effective September 24, 2020.

Collegium Appoints Rita Balice-Gordon to its Board of Directors

STOUGHTON, Mass., Sept.  14, 2020  (GLOBE NEWSWIRE) --  Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio were presented at the 14th Annual PAINWeek National Conference which took place virtually September 11-13th.

Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference

STOUGHTON, Mass., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio will be presented at the 14th Annual PAINWeek National Conference taking place virtually September 11-13th.

Collegium Announces Scientific Presentations at PAINWeek 2020 National Conference

Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2020 Results - Earnings Call Transcript

– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 –

Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020

STOUGHTON, Mass., July  21, 2020  (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, August 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Collegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

Collegium Pharmaceuticals - Whether It's Too Cheap

Amneal Pharmaceuticals

AMRX vs. COLL: Which Stock Is the Better Value Option?

AMRX vs. COLL: Which Stock Should Value Investors Buy Now?

AMRX or COLL: Which Is the Better Value Stock Right Now?

AbbVie

These are the two healthcare stocks that possess the best value for the greatest reward in May.

2 Value Stocks That Will Make You Richer in May

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2020 Results - Earnings Call Transcript

A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.

Should You Buy This Biotech That Makes A Lower Risk Painkiller?

The Call On Collegium Pharmaceuticals

Neurocrine Biosciences

COLL vs. NBIX: Which Stock Is the Better Value Option?

COLL or NBIX: Which Is the Better Value Stock Right Now?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).

Why Collegium (COLL) Could Be an Impressive Growth Stock

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2019 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Collegium Pharmaceutical (COLL) Q4 Earnings Expected to Decline

STOUGHTON, Mass., Feb.  10, 2020  (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 (the “notes”) in a public offering registered under the Securities Act of 1933, as amended.  Collegium also granted the underwriter of the notes a 30-day option to purchase up to an additional $18,750,000 principal amount of notes solely to cover over-allotments.

Collegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes Offering

Investors aren't happy about the drugmaker's proposed senior convertible note offering.

Why Collegium Pharmaceutical Shares Are Sinking Today

Collegium Pharmaceutical: 2020 Could Be A Great Year

The speciality pharmaceutical company purchased the full rights to an important drug product.

Here's Why Collegium Pharmaceutical Rose as Much as 20.7% Today

Collegium Pharmaceutical Inc. (NASDAQ: COLL) shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics.

News for Collegium Pharmaceutical Stock (COLL)